Business Watch: Investor seeks Ashland sale; WuXi sues the Pentagon

That 93-year product run is not corporate nostalgia — it is a measurable data point in the construction of one of Asia's most durable pharmaceutical companies, and it arrives as the broader biotech and specialty chemicals sector undergoes visible restructuring.

Yuhan Corp., founded in Seoul's Jongno district in 1926 by Dr. New Ilhan, marks its centennial this year. The company entered a market dominated by imported drugs under Japanese colonial rule and built its early reputation on three operational disciplines: fixed pricing, full ingredient disclosure in advertising, and targeted recruitment of overseas technical talent. In 1936, it brought in Austrian chemist Dr. Valette as technical director of its Sosabon factory in Gyeonggi Province — a deliberate transfer of formulation expertise at a time when Korea's domestic chemical capacity was thin.

What the longevity data shows

Antiphlamine, a topical anti-inflammatory analgesic launched in 1933, remains in production. Few consumer health products achieve a nine-decade shelf life. The product's persistence is a function of two early design choices: consistent formulation and systematic investment in public health literacy. Yuhan organized pre-launch lectures on tuberculosis prevention and ran a "Physicians are your friends" campaign that predated modern patient-safety frameworks by decades. The company also adopted a fixed-price policy and used a willow-tree logo gifted by independence activist Dr. Philip Jaisohn — branding decisions that translated consumer trust directly into long-term retention.

A sector in motion

Yuhan's centennial lands in a week crowded with biotech and specialty chemicals signals. As reported via PR Newswire, Matica Biotechnology has launched an integrated Korea IIT (Investigator-Initiated Trial) platform designed to accelerate global advanced therapy development. On June 18, the ASX 200 climbed with biotech and mining stocks leading the gainers, according to International Business Times Australia. Separately, C&EN's Business Watch notes that an investor is seeking a sale of specialty chemicals maker Ashland, and that WuXi has filed suit against the U.S. Department of Defense — both developments with potential consequences for cross-border contract development and manufacturing organization flows.

What to track

Three indicators will reveal whether the Yuhan model — mission-driven, trust-first, internationally networked — scales beyond a single market: first, the volume of Korean-originated advanced therapy programs advancing through Matica's IIT platform; second, the resolution timeline of the WuXi litigation and its downstream effect on U.S.–China CDMO contracts; third, whether Antiphlamine clears 100 years on pharmacy shelves in 2033. The third metric is the most concrete proxy available for long-horizon pharmaceutical discipline — and, by extension, for the kind of patient-capital model that turns a colonial-era startup into a centennial enterprise.